Welcome to our dedicated page for Unicycive Therapeutics SEC filings (Ticker: UNCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Unicycive Therapeutics filings document the regulatory, financing, governance, and operating disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on kidney disease therapies. Form 8-K reports furnish financial results and business updates, including disclosures related to oxylanthanum carbonate, NDA activity, manufacturing matters, and the company’s cash and capital resources.
The filing record also covers common stock registered on the Nasdaq Capital Market, emerging growth company status, at-the-market equity sales under a shelf registration statement, and board and executive-governance matters. Proxy materials document director elections, auditor ratification, stockholder voting mechanics, and annual meeting procedures, while other current reports address securities litigation risk tied to public statements about the OLC program.
Gupta Shalabh K. reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. reported that CEO Shalabh K. Gupta received a grant of 762,200 restricted stock units. These RSUs are payable solely in common stock and vest in three equal installments on each anniversary of the grant date over three years, conditioned on his continued service with the company. Following this grant, Gupta is reported as holding 762,200 RSUs tied to an equal number of underlying common shares.
Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sara Kenkare-Mitra received two equity awards in the form of restricted stock units. On May 14, 2026, she was granted 42,100 RSUs that vest in three equal annual installments and 84,200 RSUs that vest after one year, all settling in common stock and tied to continued service with the company. Following these grants, she holds 126,300 RSUs directly as part of her compensation, with no open-market share purchases or sales reported.
Jermasek Douglas reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. reported that EVP of Corporate Strategy Douglas Jermasek received a grant of 169,500 restricted stock units (RSUs) payable solely in common stock.
The RSU award vests in three equal installments, with 1/3 vesting on each anniversary of the grant date over three years, contingent on his continued service with the company. Following this grant, he is reported as holding 169,500 underlying shares tied to this RSU award.
Gupta Pramod reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics EVP Pramod Gupta received a grant of 169,500 restricted stock units (RSUs) payable in common stock. This equity award was granted at no cash cost to him and represents stock-based compensation rather than an open-market share purchase or sale.
According to the footnote, the RSU award vests in three equal parts: one-third on each anniversary of the grant date over three years, as long as Gupta continues his service with the company. Following this grant, he holds 169,500 RSUs directly, aligning his compensation more closely with Unicycive’s future share performance.
Unicycive Therapeutics, Inc. reported that CFO John Townsend received a grant of 169,500 restricted stock units as equity compensation. These RSUs are payable solely in common stock and carry no cash exercise price.
The RSU award vests in three equal installments, with one-third of the shares vesting on each anniversary of the grant date over three years, conditioned on Townsend’s continued service with the company. Following this grant, he holds 169,500 derivative securities linked to common stock, aligning part of his compensation with future share performance.
Laumas Sandeep reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sandeep Laumas received two restricted stock unit grants as equity compensation. One RSU award covers 42,100 underlying shares of common stock and will vest in three equal annual installments starting on the first anniversary of the grant date, contingent on continued service.
The second, annual RSU award covers 84,200 underlying shares of common stock and will vest in full one year after the grant date, also subject to his continued service with the company. Following these grants, his reported direct RSU holdings tied to these awards total 126,300 and 84,200 units, respectively.
Unicycive Therapeutics, Inc. reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah beneficially own 2,801,082 shares of Common Stock as of March 31, 2026, representing 9.99% under a disclosed ownership blocker. The filing states the Fund holds Tranche A, B and C warrants convertible into 1,097,325, 997,568 and 1,596,109 common shares respectively, but conversion is limited by a Beneficial Ownership Blocker that prevents ownership above 9.99%. Shares outstanding used for the percentage calculation were 25,237,782 shares as of March 30, 2026.
Unicycive Therapeutics reported a significantly wider loss for the first quarter of 2026, driven mainly by non-cash warrant valuation effects. Net comprehensive loss attributable to common stockholders was $12.8 million, or $(0.54) per share, compared with $0.5 million, or $0.04 per share, a year earlier.
Operating expenses were modestly higher at $8.4 million, as lower R&D spending of $1.6 million was offset by higher G&A of $6.8 million. The swing in other income to a $4.4 million expense from $8.6 million income was primarily due to an increase in the fair value of the warrant liability. As of May 11, 2026, cash, cash equivalents, and marketable securities totaled $57.1 million, which the company believes will fund planned operations into 2027.
Management highlighted preparations for the potential launch of oxylanthanum carbonate (OLC), its lead phosphate binder candidate, ahead of the June 29, 2026 PDUFA target action date for FDA review in hyperphosphatemia in dialysis patients.